GlassScriptPhysician profile
Ewen Y Tseng
NPI 1053380469
$12,894.62
in general payments reported to CMS, 2019-2025
27 companies · $4,523 in 2025
The $4,523 reported for 2025 was more than what 95% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $236 · 2021: $691 · 2022: $339 · 2023: $644 · 2024: $5,681 · 2025: $4,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $4,451 · Travel and Lodging: $3,100 · Food and Beverage: $2,297 · Debt Forgiveness: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $4,450.87 |
| Travel and Lodging | $3,099.79 |
| Food and Beverage | $2,296.95 |
| Debt Forgiveness | $1,000.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lazurite INC. | $7,746.64 | 2024-2025 | |
| Photonicare INC | $1,000.60 | 2024 | Otosight Middle Ear Scope |
| Aerin Medical INC. | $706.90 | 2023-2025 | |
| Optinose US, INC. | $548.70 | 2019-2025 | |
| Stryker Corporation | $434.73 | 2019-2025 | Scopis Ent, Clarifix |
| Intersect Ent, INC. | $389.98 | 2019-2021 | |
| Alk-Abello, INC | $355.08 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Regeneron Healthcare Solutions, INC. | $303.31 | 2019-2025 | Dupixent |
| Medtronic, INC. | $231.87 | 2023-2025 | Stealthstation S8 Platform, Bizact |
| Genzyme Corporation | $228.72 | 2019-2025 | |
| Inspire Medical Systems, INC. | $145.97 | 2023 | Inspire |
| Astrazeneca Pharmaceuticals LP | $136.57 | 2019-2025 | Tezspire |
| Kaleo, INC. | $106.51 | 2019-2023 | Auvi-Q |
| Acclarent, INC | $102.48 | 2019-2022 | |
| Smith+Nephew, INC. | $79.32 | 2023-2024 | Tula |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $62.33 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Glaxosmithkline, LLC. | $43.36 | 2021-2025 | Nucala |
| Merck Sharp & Dohme LLC | $42.75 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $37.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.86 | 2021-2022 | |
| Integra Lifesciences Corporation | $33.28 | 2022-2023 | Codman Isocool Aht, Microfrance, Instruments-Orthopedic |
| Hikma Pharmaceuticals USA | $31.36 | 2022-2024 | Ryaltris |
| Phadia US INC. | $30.19 | 2022-2023 | Immunocap |
| Ars Pharmaceuticals Operations, INC. | $26.93 | 2025 | Neffy |
| Amgen INC. | $22.55 | 2025 | Tezspire |
| Covidien LP | $10.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$391,646.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ewen Tseng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.